Biomarker development for myasthenia gravis.


Biomarkers are defined as characteristics (e.g., proteins, RNA, single nucleotide polymorphisms, imaging) that are objectively measured and evaluated as indicators of pathogenic processes or pharmacologic responses to therapeutic intervention. Biomarkers are important in clinical trials where the robust biomarker reflects the underlying disease process in a… (More)
DOI: 10.1111/j.1749-6632.2012.06787.x


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics